Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Cash from Investing Activities: 2013-2024

Historic Cash from Investing Activities for Zevra Therapeutics (ZVRA) over the last 12 years, with Dec 2024 value amounting to -$22.2 million.

  • Zevra Therapeutics' Cash from Investing Activities rose 85.41% to -$4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.4 million, marking a year-over-year increase of 303.59%. This contributed to the annual value of -$22.2 million for FY2024, which is 27.44% down from last year.
  • According to the latest figures from FY2024, Zevra Therapeutics' Cash from Investing Activities is -$22.2 million, which was down 27.44% from -$17.4 million recorded in FY2023.
  • Zevra Therapeutics' Cash from Investing Activities' 5-year high stood at -$33,000 during FY2020, with a 5-year trough of -$36.7 million in FY2022.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$22.2 million (2024), whereas its average is -$25.4 million.
  • Per our database at Business Quant, Zevra Therapeutics' Cash from Investing Activities slumped by 46,942.42% in 2021 and then skyrocketed by 52.64% in 2023.
  • Over the past 5 years, Zevra Therapeutics' Cash from Investing Activities (Yearly) stood at -$33,000 in 2020, then crashed by 46,942.42% to -$15.5 million in 2021, then tumbled by 136.53% to -$36.7 million in 2022, then surged by 52.64% to -$17.4 million in 2023, then dropped by 27.44% to -$22.2 million in 2024.